Biosidus is a global company making a difference in millions of patients’ lives around the world by providing access in emerging markets to complex biological drugs that effectively treat chronic medical conditions and rare or life-threatening diseases.
Biosimilars are similar in structure and function to reference biological drugs on which they are based. The patents on the originals have expired so the biosimilars can provide similarly efficacious treatment at lower costs. Over 30 years, Biosidus’ R&D team have developed nine biosimilars that are commercially manufactured at our fully integrated Almagro drug substance and Bernal drug product fill-finish facilities in Buenos Aires, Argentina.
Biosidus has also signed licensing agreements with large pharmaceutical companies to supplement our own portfolio with other third-party biological drugs, and we distribute products across a large network of emerging markets – bringing essential treatments to the large populations who need them.
Our Regulatory Affairs and Pharmacovigilance Department covers the regulatory requirements for approved products in more than 40 countries and ongoing registration procedures in another 20 countries. We have an excellent track record of quality, and products in various formulations and formats are distributed from our logistics center in Buenos Aires to over 60 countries worldwide.
We have a highly talented team that is extremely proud of our company and the difference we make to quality of life for tens of millions of patients in emerging markets around the world.
Biosidus wants to be the leader in biosimilars in developing countries.
“We want to contribute to the improvement in people’s health and quality of life by developing and manufacturing drug products that meet international standards of quality.”
We have good practices in safety and hygiene and environmental health.
Research, development and manufacturing of raw materials resulting from biotechnologies, with a warehouse and a quality control laboratory in the Ciudad Autónoma de Buenos Aires plant.
IQNET CERTIFICATEResearch, development and manufacturing of raw materials resulting from biotechnologies, with a warehouse and a quality control laboratory in the Ciudad Autónoma de Buenos Aires plant.
IQNET CERTIFICATEDevelopment of medical products presented in a formulation as injectable lyophilized liquids that include biotechnological active substances and not beta-lactam, cytostatic or hormonal active substances. Manufacturing of glass vials with diluents that include secondary package and quality control. Exportation of medical specialties. Activities carried out in the Bernal plant.
IQNET CERTIFICATEDevelopment of medical specialties presented in a formulation as injectable lyophilized liquids that include biotechnological active substances and not beta-lactam, cytostatic or hormonal active substances. Manufacturing of glass vials with diluents that include secondary package and quality control. Exportation of medical specialties. Activities carried out in the Bernal plant.
IQNET CERTIFICATEWomen’s economic empowerment is at the core of the United Nations Women agenda. The concept does not only mean that women should have their own income, but that they should also have control over those resources, and the ability to make their own choices and decisions in processes whereby people raise awareness of their rights, abilities and interests.
We were finalists as a result of our practices. The aspects that were taken into account were:
Diversity practice integration in the management, internal policies on diversity management and multiplying the action in the society.